Skip to Main Content
Our Commitment to Diversity


Jacqueline Fu

Acted as Taiwan counsel to Aslan Pharmaceuticals in its ADSs initial offering of US$42 million on the Nasdaq Stock Market.

Acted as Taiwan counsel to Taiwan Liposome Company Ltd in its ADSs listing on the Nasdaq Stock Market.

Acted as Issuer Counsel to Aslan Pharmaceuticals in its listing on the Taipei Exchange.

Represented II-VI in its acquisition of CoAdna for US$85 million.

Represented General Motors in its acquisition of the dealer distribution network of China Automobile Co., Ltd. throughout Taiwan.

Represented  Taiwan listed company in its acquisition of MassMutual Mercuries Life Insurance.

Represented the bidder company on the acquisitions of AIG Insurance and Metlife Inc.

Represent Sartorius in acquisition of its Taiwan distributor.

Represented CERATIZIT in its acquisition of a 50% stake in carbide manufacturer CB Carbide, including eight factories and a dozen sales offices.

Represent Mirae Asset's sale of its Taiwan subsidiary to Amundi Asset.

Represented Intel Capital in Taiwan in relation to Asia Pacific venture capital transactions.
Represented Sequoia Capital in its investments in Appier and Pinko.

Represented TaiGen Pharmaceuticals Group in its US$120 million in total preferred stock equity financings of Series A, B and C.

Represented Taiwan listed company in bidding on acquisition of McDonalds restaurants in Taiwan.

Represented ACT Genomics in its corporate restructuring and equity financing.

Represented GE Aircraft Engine in its joint venture with Evergreen International Corporation, a subsidiary of EVA Airways.

 Represented Handa Pharmaceuticals in PHARMIRA LABORATORIES, INC’s acquisition of Handa and subsequent equity financing.

Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel